Evidence map›Paper›PMID 35236936›Full record

ArticleBritish journal of cancer2022

Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma.

Yu-Yun Shao, Pai-Sheng Chen, Liang-In Lin, Bin-Shyun Lee, Andrew Ling, Ann-Lii Cheng, Chiun Hsu, Da-Liang Ou

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. NCancer science · 2023
    Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Yu-Yun Shao *Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei City, 10055, Taiwan.
Pai-Sheng Chen *Department of Medical Laboratory Science and Biotechnology, National Cheng Kung University, Tainan City, 70101, Taiwan.
Liang-In LinGraduate Institute of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei City, 10048, Taiwan.ORCID http://orcid.org/0000-0002-3561-1093
Bin-Shyun LeeGraduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei City, 10055, Taiwan.
Andrew LingColumbia University Vagelos College of Physicians and Surgeons, New York, NY, 10032, USA.
Ann-Lii ChengGraduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei City, 10055, Taiwan.ORCID http://orcid.org/0000-0002-9152-6512
Chiun HsuGraduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei City, 10055, Taiwan.
Da-Liang OuGraduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei City, 10055, Taiwan. dlou@ntu.edu.tw.ORCID http://orcid.org/0000-0002-8368-1141
National Taiwan University · TWColumbia University · USNational Cheng Kung University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSorafenib is one of the standard first-line therapies for advanced hepatocellular carcinoma (HCC). Unfortunately, there are currently no appropriate biomarkers to predict the clinical efficacy of sorafenib in HCC patients. MicroRNAs (miRNAs) have been studied for their biological functions and clinical applications in human cancers.

methodsIn this study, we found that miR-10b-3p expression was suppressed in sorafenib-resistant HCC cell lines through miRNA microarray analysis.

resultsSorafenib-induced apoptosis in HCC cells was significantly enhanced by miR-10b-3p overexpression and partially abrogated by miR-10b-3p depletion. Among 45 patients who received sorafenib for advanced HCC, those with high miR-10b-3p levels, compared to those with low levels, exhibited significantly longer overall survival (OS) (median, 13.9 vs. 3.5 months, p = 0.021), suggesting that high serum miR-10b-3p level in patients treated with sorafenib for advanced HCC serves as a biomarker for predicting sorafenib efficacy. Furthermore, we confirmed that cyclin E1, a known promoter of sorafenib resistance reported by our previous study, is the downstream target for miR-10b-3p in HCC cells.

conclusionsThis study not only identified the molecular target for miR-10b-3p, but also provided evidence that circulating miR-10b-3p may be used as a biomarker for predicting sorafenib sensitivity in patients with HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMicroRNAsSorafenibApoptosisCell Line, TumorCell ProliferationDrug Resistance, NeoplasmHumansMicroRNAsMIRN10 microRNA, humanSorafenib

Identifiers

PMID35236936
PMCPMC9174288
OpenAlexW4214809085

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.